Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Anticancer Res. 2023 Oct;43(10):4619-4626. doi: 10.21873/anticanres.16656.
BACKGROUND/AIM: The percentage of positive cores (PPC) is increasingly recognized as a prognostic factor in prostate cancer. However, the usefulness of PPC for patients undergoing androgen deprivation therapy (ADT) and high-risk group has not been adequately studied.
A retrospective analysis was conducted of 255 patients who underwent prostate biopsy (all-case group). We examined the efficacy of PPC as a prognostic biomarker.
Eighty-nine patients were treated with ADT alone (ADT group), and 107 patients were classified as high-risk (high-risk group). The median duration of follow-up was 112.4 months, 85.3 months, and 110.0 months for the all-case, ADT, and high-risk groups, respectively. Patients with PPC >60% had significantly shorter prostate cancer-specific survival (CSS) and castration-resistant prostate cancer-free survival (CFS) in the all-case and ADT groups. In the high-risk group, patients with PPC >60% had shorter CFS but no difference in CSS. Multivariate analysis showed that significant independent predictors of prostate CSS were the presence of metastasis at diagnosis and PPC >60% in the all-case and ADT groups.
PPC may be a prognostic factor in ADT treated and high-risk prostate patients.
背景/目的：阳性核心百分比（PPC）越来越被认为是前列腺癌的预后因素。然而，PPC 对于接受雄激素剥夺治疗（ADT）和高危组患者的作用尚未得到充分研究。
回顾性分析了 255 例接受前列腺活检的患者（所有病例组）。我们研究了 PPC 作为预后生物标志物的疗效。
89 例患者单独接受 ADT 治疗（ADT 组），107 例患者被归类为高危（高危组）。所有病例、ADT 和高危组的中位随访时间分别为 112.4 个月、85.3 个月和 110.0 个月。所有病例组和 ADT 组中，PPC>60%的患者前列腺癌特异性生存（CSS）和去势抵抗性前列腺癌无复发生存（CFS）明显缩短。在高危组中，PPC>60%的患者 CFS 缩短，但 CSS 无差异。多变量分析显示，所有病例组和 ADT 组中，诊断时存在转移和 PPC>60%是 CSS 的显著独立预测因素。
PPC 可能是 ADT 治疗和高危前列腺患者的预后因素。
